Guardant Health’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Guardant Health develops a non-invasive digital sequencing technology that provides genomic liquid biopsy testing services for cancer diagnostics. Read more

Helmy Eltoukhy's photo - Co-Founder & CEO of Guardant Health

Co-Founder & CEO

Helmy Eltoukhy

CEO Approval Rating

78/100

Founded:

2013

Status:

PublicNASDAQGH

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Roche is one of Guardant Health's top competitors. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Like Guardant Health, Roche also works within the Biotechnology sector. Roche has 97,546 more employees than Guardant Health.

Thermo Fisher is Guardant Health's #2 rival. Thermo Fisher was founded in 1956 in Waltham, Massachusetts. Thermo Fisher competes in the Health Care Equipment field. Thermo Fisher generates $26B more revenue than Guardant Health.

Illumina is a top competitor of Guardant Health. Illumina is a Public company that was founded in San Diego, California in 1998. Illumina is in the Biotechnology industry. Illumina has 7,246 more employees vs. Guardant Health.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is PGDx a competitor of Guardant Health?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$257.6M

Guardant Health's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 5B. Over the last four quarters, Guardant Health's revenue has grown by 9%. Specifically, in Q2 2020's revenue was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, it was $62.9M; in Q3 2019, Guardant Health's revenue was $60.8M.

Acquisitions

No recent acquisitions found related to Guardant Health

Guardant Health Funding History

$9.2M$96.7M$179.6M$539.6M$777.1M

Since Guardant Health was founded in 2013, it has participated in 6 rounds of funding. In total Guardant Health has raised $777.1M. Guardant Health's last funding round was on Oct 2018 for a total of $237.5M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Oct 2018
$237.5M
-
Series E
May 2017
$360M

SoftBank Group

Series D
Dec 2015
$82.8M
Series C
Dec 2014
$56M
Series B
Apr 2014
$31.5M

Total Funding: $777.1M

Since Guardant Health was founded in 2013, it has participated in 6 rounds of funding. In total Guardant Health has raised $777.1M. Guardant Health's last funding round was on Oct 2018 for a total of $237.5M

Investments

No recent investments found related to Guardant Health

Guardant Health News

August 24, 2020Investor’s Business Daily

Guardant Health Coronavirus Test Gets Emergency OK; GH Stock Nears Buy Point

Guardant Health on Monday announced that the U.S. Food and Drug Administration granted emergency use ... See more »
August 20, 2020Zolmax News

Morgan Stanley Has $348.83 Million Holdings in Guardant Health Inc (NASDAQ:GH)

Morgan Stanley cut its holdings in shares of Guardant Health Inc (NASDAQ:GH) by 2.3% during the 1st q... See more »
August 10, 2020MedCity News

Guardant scores FDA approval for liquid biopsy test

In a phone interview, Guardant Health CEO Helmy Eltoukhy said he expected the approval to encourage c... See more »
August 7, 2020The Business Journals: San Francisco Business Times

Cancer blood test developer Guardant Health signs South Bay's largest office lease of 2020

The company is taking two levels at Hewlett Packard Enterprise Co.'s former headquarters in Palo Alto... See more »

Guardant Health Blogs

January 9, 2018Guardant Health Blog

Praesent ut ligula non mi

Praesent egestas tristique nibh. Aliquam eu nunc. Nunc egestas, augue at pellentesque laoreet, felis ... See more »
January 9, 2018Guardant Health Blog

Cras risus ipsum faucibus ut

Praesent egestas tristique nibh. Aliquam eu nunc. Nunc egestas, augue at pellentesque laoreet, felis ... See more »
January 9, 2018Guardant Health Blog

Donec quam felis ultricies nec

Praesent egestas tristique nibh. Aliquam eu nunc. Nunc egestas, augue at pellentesque laoreet, felis ... See more »
January 9, 2018Guardant Health Blog

Phasellus nec sem in justo

Praesent egestas tristique nibh. Aliquam eu nunc. Nunc egestas, augue at pellentesque laoreet, felis ... See more »
March 21, 2017Guardant Health Blog

Liquid biopsy offers advantages over traditional tissue biopsy for detecting resistance alterations in patients with advanced cholangiocarcinoma

REDWOOD CITY, Calif. – March 21, 2017 — New findings from researchers at Massachusetts General ... See more »
January 13, 2017Guardant Health Blog

The clinical significance of tumor heterogeneity

  Traditionally, oncologists believed that solid-cancer tumors were largely homogeneous – that t... See more »
December 5, 2016Guardant Health Blog

Largest ever study of non-small cell lung cancer patient cell-free circulating tumor DNA adds to growing evidence of Guardant360’s utility in guiding treatment decisions

VIENNA, Dec. 5, 2016 – Guardant Health reported the results of the largest ever genomic study of adva... See more »

Guardant Health Press Releases

April 30, 2020centralcharts

Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020

REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today ann... See more »
August 7, 2019CentralCharts

Guardant Health Reports Second Quarter 2019 Financial Results and Raises 2019 Revenue Guidance

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer c... See more »
May 29, 2019GlobeNewswire

Guardant Health to Present at the William Blair 2019 Growth Stock Conference

REDWOOD CITY, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading ... See more »
May 4, 2019CentralCharts

Guardant Health to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer c... See more »
April 15, 2019streetinsider

NILE Study Results Demonstrating Guardant360's High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research

REDWOOD CITY, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announce... See more »
April 9, 2019GlobeNewswire

Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360

REDWOOD CITY, Calif., April 09, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announce... See more »
March 28, 2019GlobalNewswire

Palmetto GBA issues Draft Local Coverage Determination Expanding Guardant360 Medicare Coverage to Most Solid Tumor Types

REDWOOD CITY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announce... See more »

Guardant Health Videos

February 21, 2017Guardant Health Vimeo Channel

"Guillermo's Story" on VIMEO

Meet Guillermo, a Chicago truck driver with stage IV gastric cancer.Cast: Guardant Health... See more »
December 18, 2015Guardant Health Vimeo Channel

"A case of lung adenocarcinoma 1" on VIMEO

Guardant Health Chief Medical Officer Rick Lanman describes a case where Guardan360 helped a patient ... See more »
December 18, 2015Guardant Health Vimeo Channel

"Our report" on VIMEO

Certified Genetic Counselor Kimberly Banks discusses how we organize information in the Guardant360 r... See more »
December 18, 2015Guardant Health Vimeo Channel

"Our validation studies" on VIMEO

Guardant360 has been extensively validated and found to have greater than 99.9999% analytical specifi... See more »
December 18, 2015Guardant Health Vimeo Channel

"Interpreting low mutant allele frequency" on VIMEO

Because of Guardant360's high sensitivity and specificity, it can detect alterations at very low muta... See more »
December 18, 2015Guardant Health Vimeo Channel

"Our case studies" on VIMEO

Chief Medical Officer Rick Lanman discusses three interesting cases where Guardant360 led to a dramat... See more »
December 18, 2015Guardant Health Vimeo Channel

"How Guardant360 handles germline mutations" on VIMEO

Guardant360 looks for somatic genomic alterations, but occasionally finds a germline mutation. Certif... See more »

Social Statistics

Headquarters

505 Penobscot Drive

Redwood City, California94063

1-855-698-8887

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Guardant Health develops a non-invasive digital sequencing technology that provides genomic liquid biopsy testing services for cancer diagnostics. Guardant Health was founded in 2013. Guardant Health's headquarters is located in Redwood City, Californ...

CEO

Guardant Health's Co-Founder & CEO, Helmy Eltoukhy, currently has an approval rating of 78%. Guardant Health's primary competitors are Roche, Thermo Fisher & Illumina.

Website

guardanthealth.com

Frequently Asked Questions about Guardant Health

  1. When was Guardant Health founded?

    Guardant Health was founded in 2013
  2. Who is Guardant Health's CEO?

    Guardant Health's CEO is Helmy Eltoukhy
  3. How much revenue does Guardant Health generate?

    Guardant Health generates $257.6M in revenue
  4. How much funding does Guardant Health have?

    Guardant Health has historically raised $777.1M in funding
  1. Where is Guardant Health's headquarters?

    Guardant Health's headquarters is in Redwood City California, USA
  2. How many employees does Guardant Health have?

    Guardant Health has 454 employees
  3. What sector does Guardant Health operate in?

    Guardant Health is in Biotechnology
  4. Who are Guardant Health's competitors?

    Guardant Health's top competitors are Roche, Thermo Fisher, Illumina